Group 1 - Cibus, Inc. will report its first quarter 2025 financial results on May 8, 2025, and will host a conference call at 4:30 p.m. ET to discuss these results and other updates [1][2][3] - The company specializes in agricultural biotechnology, focusing on gene editing technologies to develop specific traits in seeds, addressing productivity and sustainability challenges for farmers [4] - Cibus is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties, with a long-term focus on major global row crops such as canola, corn, rice, soybean, and wheat [4] Group 2 - The company has developed a pipeline of five productivity traits, including weed management in rice, pod shatter reduction, and sclerotinia resistance, which are its near-term focus [4] - The global economic impact of diseases and pests on agriculture is estimated to be approximately $300 billion annually, highlighting the importance of Cibus' innovations [4]

Financial Data and Key Metrics Changes - Cash and cash equivalents were $14.4 million as of December 31, 2024, with $21.6 million net proceeds received in 2025 from a registered direct offering [37] - R&D expense decreased to $12.4 million for Q4 2024 from $14.2 million in the previous year, primarily due to lower non-cash stock compensation and cost-saving initiatives [38] - Net loss improved to $25.8 million for Q4 2024 compared to a net loss of $277.2 million in the prior year, which included a non-cash goodwill impairment charge of $249 million [38] Business Line Data and Key Metrics Changes - The rice platform is gaining momentum with collaborations affirming herbicide resistance traits, and agreements with four major rice seed companies covering approximately 40% of accessible rice acres [15][16] - In canola, Cibus has developed productivity traits for Pod Shatter Reduction and continues to progress on advanced traits for disease resistance and herbicide tolerance [18][19] - The soybean platform achieved a significant milestone with successful editing of soybean cells for HT2 traits, allowing access to an estimated 125 million accessible soybean acres [26][27] Market Data and Key Metrics Changes - The global regulatory environment is evolving favorably, with the EU's pending legislation expected to regulate gene-edited plants similarly to conventional breeding, opening new markets for Cibus [29][30] - The California Rice Commission approved planned field trials for advanced rice traits, marking a significant milestone in a key American market [30] Company Strategy and Development Direction - Cibus is transitioning from an agricultural trait development company to a commercial trait company, focusing on gene-edited productivity traits that address sustainability challenges for farmers [8][9] - The company emphasizes its proprietary Rapid Trait Development System (RTDS) as a key differentiator, enabling rapid and predictable trait development [14] - Cibus is also advancing its Sustainable Ingredients program, targeting low carbon ingredients and biofragrances for the consumer packaged goods industry [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in key markets and the potential for significant value capture as regulatory frameworks evolve [41][42] - The company is positioned to capitalize on the global adoption of gene-edited solutions, with traits moving into customer germplasm and showing promising results in field trials [42] Other Important Information - Cibus expects existing cash and cash equivalents to fund planned operating expenses into late Q3 2025, supported by recent financing [37][64] - The company is focused on achieving several important milestones in 2025, including the completion of EU legislation and continued development of its soybean platform [34][35] Q&A Session Summary Question: What does the EU decision mean for commercial products in Europe? - Management highlighted the importance of the EU's regulatory process and its implications for accelerating customer programs and trade [46][49] Question: Can you discuss the patentability of genetic modifications under the current EU law? - Management noted that the EU Council advocates for transparency in patenting, which is seen as beneficial for the seed industry [52][54] Question: Are commercialization dates for products on track? - Management confirmed that all timelines are on track, with significant progress expected in the current year [58][60] Question: Will there be meaningful revenues from the sustainable ingredient business in 2026? - Management expressed confidence in generating revenues from biofragrance products in 2026, indicating strong market interest [68][70] Question: Are you in touch with potential customers in Europe? - Management confirmed ongoing collaboration with European customers on various traits, including Sclerotinia tolerance [72][74] Question: What are the expectations for operating costs moving forward? - Management indicated that while current cost reductions are significant, further optimizations are expected as processes are refined [76][78] Question: What priority traits and crops will receive the most resources? - Management emphasized focus on rice, canola, and soybean platforms, particularly in disease resistance and productivity traits [84][86]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024; or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission file number 001-38161 Cibus, Inc. (Exact name of registrant as specified in its charter) _____________________ (S ...

Cibus Reports Fourth Quarter Financial Results and Provides Business Update A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collabor ...

A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collaboration with Albaugh LLC and RTDC Corporation Limited continues to strengthen ...

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like’ category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its ...

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its ...

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Titl ...

Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment Cibus' white mold resistance traits are expected to help preserve crop yields and reduce fungicide usage for farmers SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that ...

Initial bioassay data for Cibus’ third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment Cibus’ white mold resistance traits are expected to help preserve crop yields and reduce fungicide usage for farmers SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced tha ...